Background: The activating immune ligand, MICA, acts as a "kill me" signal through the NKG2D receptor expressed on natural killer (NK) cells that are key players in the fight against breast cancer (BC). Shedding of MICA during BC progression acts as a formidable barrier against NK cells' immune-surveillance. Recently, miR-20a was found to mediate immune escape through repressing MICA levels on BC cells. However, targeting miR20a/MICA using natural compounds has seldomly been investigated. Vitexin, a flavone Cglycoside, showed potent anticancer properties. It was reported that acetylation of glycosides increases their cytotoxic activity, with an unknown impact on immunogenicity. Our group has successfully isolated 3'-O-acetylvitexin from Ocimum basilicum which showed potent cytotoxic effects against colon cancer cells but has never been investigated in BC. Our aim is to unravel the role of the immunogenic miR-20a/MICA axis in BC patients and its regulation by vitexin and 3'-O-acetylvitexin. Methods: Breast tissues were collected from 26 BC patients. ER, PR and HER2 expression was quantified using immunohistochemistry. MDA-MB-231 TNBC cells and MCF-7 HRþ BC cells were treated with serial dilutions of vitexin and 3'-O-acetylvitexin. Their cytotoxic activities were assessed using MTT, colony forming and migration assays. Total RNA was extracted, reverse transcribed, then MICA and miR-20a were quantified using qRT-PCR. Results: miR-20a is upregulated in BC patients, while MICA was downregulated in MDA-MB-231 compared to MCF7 cells. Vitexin decreased MDA-MB-231 cellular viability and migration capacity. 3'-O-acetylvitexin resulted in a more pronounced dosedependent repression of TNBC cellular viability, colonogenicity and migration capacity. Treatment with vitexin didn't show any alteration in miR-20a but showed only 2 folds increase in MICA. However, 3'-O-acetylvitexin markedly decreased miR20a with a concomitant increase in MICA by 12 folds. Conclusions: 3'-O-acetylvitexin displays more pronounced anticancer properties against TNBC through halting their progression and immune suppressive nature by modulating miR-20a/MICA axis. This highlights miR-20a/MICA axis as a potential therapeutic target in BC.
51P DNA damage ATR/Chk1 checkpoint signalling increases PD-L1 immune checkpoint activation and its implication for personalised combination therapy Medical Oncology, Fortis Balaji Hospital, Jodhpur, India Background: DNA double-strand break (DSB) is the most critical type of genotoxic stress. Clinical studies have revealed a link between genomic instability and response to anti-PD-1/PD-L1 therapy in cancer management. We investigated role of DBS repair and ATR/Chk1 DNA damage checkpoint in regulating PD-L1 expression and their use in therapy selection and study design. Methods: Protein expression data proteins and phosphoproteins with major clinical outcome endpoints were obtained from The Cancer Genome Atlas project. A statistical correlation analysis was performed between the expression and distribution DBS repair and ATR/Chk1 DNA damage checkpoint pathway and PD-L1. Signaling network was also analysed for of therapeutic target identification. Results: The expression and distribution patterns of PD-L1 was measured in 7694 samples from 32 cancer type. Increased expression of PD-L1 was associated with higher tumor stage and grade. Analyses of the DNA damage ATR/Chk1 checkpoint signalling revealed strong correlation of PDL1 expression. PD-L1 expression in was upregulated in response to DSBs with strong correlation with MRE11 (correlation coefficient (r) ¼0.39, p < 0.01), RAD51 (r ¼ 0.33, p < 0.01). This upregulation requires ATM/ATR/ Chk1 kinases (Chk2_pt68; r ¼ 0.36, p < 0.01 and Chk1_ps296; r ¼ 0.33, p < 0.01). Interestingly Jab-1 expression was corelated with both Chk-1(r ¼ 0.27, p < 0.01) and PD-L1 (r ¼ 0.22, p < 0.01). We further investigate for the possible signaling mechanism for the correlation and found activation of oncogenic signaling in a cancer type specific manner. PI3K/AKT/mTOR/S6K, INFgamma/ JAK/STAT/IRF1 and Ras/BRAF/MEK/ ERK were involved in mechanism of increased PD-L1 expression. Conclusions: DSB-mediated immune activation is balanced by concomitant inhibitory signaling, via the checkpoint kinases ATM, ATR, and Chk1 drived PD-L1 expression in tumors. These observations have important clinical implications for therapy selection, particularly following progression on DNA damaging agents suggesting that PD-1/PD-L1 inhibitors may be a useful therapeutic strategy (with or without concurrent DNA damaging agents) for tumors. Legal entity responsible for the study: Narender Kumar. Background: In recent years, immunotherapy has shown remarkable success in the treatment of several cancers. Masking PDL-1 on cancer cellular surface or PD1 on Tcells may increase the lymphocyte activity against the tumor. Intracellular regulation of PDL-1 may thus be a promising therapeutic strategy. However, the mechanism regulating PDL-1 expression remains unclear. Moreover, there are evidences supporting the idea that deregulation of Hedgehog (Hh) signalling has a role in immunity and inflammation. Therefore, we investigated whether activation of the Hh signalling contributes to regulate PDL-1 or PD1 expression and whether its pharmacological modulation affects the anti-tumor function of activated lymphocytes. Methods: We used a panel of human pancreatic and breast cancer cell lines, with different ER, PR and HER2 expression patterns. The effects induced by Hh inhibition, through the Smo-inhibitor NVP-LDE225, on signal transduction in cancer cells were investigated. We also tested how the overexpression of GLI1, tGLI1 and GLI3, main transcription factors in the Hh pathway, could affect the expression of PDL1. Results: Hh inhibition reduced the expression of PDL1 in all analysed cell lines. This effect is counteracted by upregulation of PDL-1, when GLI1 and, even more, tGLI1 are overexpressed. NVP-LDE225 treatment modulates the production of several secreted factors, such as secreted IL6-receptor which acts as an anti-inflammatory molecule. Conclusions: Our results suggest that Hh pathway has a specific role in cancer immune evasion trough PDL-1 modulation. 
